fbpx

The Digest

Pharma news roundup and Larvol updates

Contact Us
Month: September 2019

Weekly Top News – Breast Cancer – September 30, 2019

September 30, 2019

Tecentriq (atezolizumab) / Roche
Health Canada approves Tecentriq in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer (Canada Newswire) – Sep 27, 2019 – “Hoffmann-La Roche Limited (Roche Canada) announced today that Health Canada under the Notice of Compliance with Conditions (NOC/c) policy has approved Tecentriq® (atezolizumab) in combination with chemotherapy (nab-paclitaxel) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1%, and who have not received prior chemotherapy for metastatic disease. Tecentriq is the first and only approved cancer immunotherapy agent in Canada for first-line TNBC. This approval meets a significant unmet need for TNBC patients…This approval is based on results from the randomized Phase III IMpassion130 study.”

 

Verzenio (abemaciclib) / Eli Lilly
Verzenio (abemaciclib) significantly extends life by a median of 9.4 months for women with HR+, HER2- advanced breast cancer in MONARCH 2 study (Eli Lilly Press Release) – Sep 29, 2019 – P3, N=669; MONARCH 2 (NCT02107703); Sponsor: Eli Lilly; “Eli Lilly and Company…announced Verzenio® (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer previously treated with endocrine therapy (median of 46.7 months vs. median of 37.3 months with placebo plus fulvestrant; HR: 0.757; 95% CI: 0.606, 0.945; P = 0.0137). Results from the Phase 3 MONARCH 2 clinical trial, which included both pre/peri- and postmenopausal women, were consistent across subgroups.”

 

Keytruda (pembrolizumab) / Merck (MSD)
Merck’s Keytruda (pembrolizumab) plus chemotherapy showed statistically significant increase in pathological complete response versus chemotherapy as neoadjuvant therapy in early-stage triple-negative breast cancer (TNBC) (Merck (MSD) Press Release) – Sep 29, 2019 – P3, N=1,174; KEYNOTE-522 (NCT03036488); Sponsor: Merck Sharp & Dohme Corp; “Merck…announced results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial in patients with early-stage triple-negative breast cancer (TNBC)…In the neoadjuvant phase, KEYTRUDA plus chemotherapy (n=401) resulted in a statistically significant increase in pathological complete response (pCR) versus chemotherapy (n=201), from 51.2% with neoadjuvant chemotherapy to 64.8% for neoadjuvant KEYTRUDA plus chemotherapy, in patients with early-stage TNBC (p=0.00055)….In the PD-L1 CPS ≥1 subgroup, the rates of pCR were 68.9% for neoadjuvant KEYTRUDA plus chemotherapy (n=334) versus 54.9% for neoadjuvant chemotherapy (n=164).”

 

Kisqali (ribociclib) / Novartis
Novartis Kisqali delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients (Novartis Press Release) – Sep 29, 2019 – P3, N=726; MONALEESA-3 (NCT02422615); Sponsor: Novartis Pharmaceuticals; “Novartis today announced results from the MONALEESA-3 trial, which showed Kisqali® (ribociclib) achieved statistically significant improvement in overall survival (OS)…MONALEESA-3 evaluated efficacy and safety of Kisqali plus fulvestrant in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer….Median PFS in the first-line was also reached at this analysis and demonstrated that Kisqali in combination with fulvestrant has a median PFS of 33.6 months compared to 19.2 months in the placebo arm (HR=0.546; 95% CI: 0.415-0.718).”

 

Lenvima (lenvatinib) / Eisai, Merck (MSD); Keytruda (pembrolizumab) / Merck (MSD)
Eisai announces data presentations on Keytruda (pembrolizumab) plus Lenvima (lenvatinib) investigational combination therapy and Halaven (eribulin) at ESMO 2019 (PRNewswire) – Sep 24, 2019 – P3, N=720; ENGOT-en9 (NCT03884101); Sponsor: Merck Sharp & Dohme Corp; P3, N=392; SELECT (NCT01321554); Sponsor: Eisai Inc; P3, N=694; LEAP-011 (NCT03898180); Sponsor: Merck Sharp & Dohme Corp; “Eisai today announced the presentation of new data and analyses via one oral proffered paper presentation, four poster discussions and seven poster presentations at the 2019 European Society for Medical Oncology (ESMO) Annual Meeting from September 27 – October 1 in Barcelona, Spain. Data to be presented include posters on the ongoing trials evaluating pembrolizumab plus lenvatinib…”

 

Tecentriq (atezolizumab) / Roche; sacituzumab govitecan (IMMU-132) / Immunomedics
Immunomedics provides corporate update (GlobeNewswire) – Sep 28, 2019 – “The collaboration with Roche will evaluate the safety and efficacy of the combination of atezolizumab (Tecentriq®)…and sacituzumab govitecan, as a frontline treatment of patients with metastatic or inoperable locally advanced TNBC…. The open-label, multicenter, randomized Phase 1b/2 study will be conducted as part of MORPHEUS…. Roche will be responsible for conducting the randomized trial….Immunomedics and the GBG Forschungs-GmbH (GBG), Neu-Isenburg, Germany, have entered into a collaboration to develop sacituzumab govitecan as a treatment for newly-diagnosed breast cancer patients who do not achieve a pathological complete response (pCR) following standard neoadjuvant therapy…. The multinational, post-neoadjuvant Phase 3 SASCIA study developed by GBG will be conducted under the sponsorship of GBG.”

 

Cyramza (ramucirumab) / Eli Lilly; Tarceva (erlotinib) / Astellas, Roche; pemetrexed / Generic Mfg.; Verzenio (abemaciclib) / Eli Lilly; Keytruda (pembrolizumab) / Merck (MSD)
Lilly Oncology to present robust data across its growing portfolio at ESMO 2019 (Eli Lilly Press Release) – Sep 23, 2019 – P3, N=669; MONARCH 2 (NCT02107703); Sponsor: Eli Lilly and Company; P1/2, N=970; LIBRETTO-001 (NCT03157128); Sponsor: Loxo Oncology, Inc; P3, N=543; RELAY (NCT02411448); Sponsor: Eli Lilly and Company; “Verzenio® (abemaciclib) Phase 3 data included in ESMO Presidential Symposium and Official Press Program: Positive overall survival results to be presented from MONARCH 2, evaluating Verzenio with fulvestrant for the treatment of women with HR+, HER2- advanced breast cancer whose cancer grew or spread following endocrine therapy; RET-altered thyroid cancer data for selpercatinib (LOXO-292) from the Phase 1/2 LIBRETTO-001 study to be featured in late-breaking oral presentation; Lung cancer highlights to include presentation of data from the Phase 3 CYRAMZA® (ramucirumab) RELAY trial and studies of the ALIMTA® (pemetrexed)-KEYTRUDA® (pembrolizumab)-platinum chemotherapy combination.”

 

Keytruda (pembrolizumab) / Merck (MSD); Opdivo (nivolumab) / Ono Pharma, BMS; Kadcyla (ado-trastuzumab emtansine) / Roche; Ibrance (palbociclib) / Pfizer
Flatiron Health announces research to be presented at European Society for Medical Oncology Congress 2019 (Businesswire) – Sep 26, 2019 – “Flatiron Health today announced 13 abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2019, which will be held September 27 – October 1, 2019, in Barcelona, Spain. The research, spanning multiple tumor types and areas of study, utilized Flatiron’s high-quality, real-world oncology datasets.”

 

Ibrance (palbociclib) / Pfizer
Pfizer presents new evidence of Ibrance (palbociclib) effectiveness in HR+, HER2- metastatic breast cancer patients in four real-world studies at ESMO Congress 2019 (Businesswire) – Sep 24, 2019 – “Pfizer Inc….announced the presentation of four IBRANCE® (palbociclib) real-world analyses. The studies support the effectiveness of IBRANCE combination therapy in everyday clinical practice and provide additional insights on its use in certain patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). The posters will be presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain on Sunday, September 29.”

 

Kadcyla (ado-trastuzumab emtansine) / Roche; Tecentriq (atezolizumab) / Roche
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress (Roche Press Release) – Sep 23, 2019 – “Roche…announced that results from a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress, taking place from 27 September – 1 October in Barcelona, Spain. A total of 100 abstracts and 15 late-breaking abstracts that include a Roche medicine will be presented at this year’s congress….First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer….First results from the BFAST study testing Foundation Medicine’s FoundationOne® Liquid biopsy assay to identify patients who may be eligible for Alecensa® (alectinib)….First results from the positive Phase III IMpower110 study of Tecentriq® (atezolizumab) monotherapy as an initial treatment for advanced lung cancer.”

Read More …

Weekly Top News – IBD – September 30, 2019

September 30, 2019

Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
RedHill Biopharma provides H2/2019 R&D update (GlobeNewswire) – Sep 26, 2019 – “…the last patient enrolled in the open-label extension Phase 3 study with RHB-104 in Crohn’s disease (MAP US2 study) has recently completed their participation in the study. A total of 30 subjects completed 52 weeks of treatment with RHB-104 in the MAP US2 study, with top-line results expected in the fourth quarter of 2019.”

 

etrasimod (APD334) / Arena
Arena Pharmaceuticals presented new data from the phase 2 OASIS trial for etrasimod at the World Congress of Gastroenterology Meeting (PRNewswire) – Sep 26, 2019 – P2, N=156; OASIS (NCT02447302); Sponsor: Arena Pharmaceuticals; “Arena Pharmaceuticals, Inc…presented new data from the Phase 2 OASIS trial for etrasimod…in development for a range of immune-mediated and inflammatory conditions…These data were presented at the World Congress of Gastroenterology Meeting in Istanbul, Turkey. ‘Steady-state etrasimod trough concentrations were achieved and maintained from weeks 1 to 12 in patients with moderately to severely active ulcerative colitis….”

 

Humira (adalimumab) / Eisai, AbbVie; Remicade (infliximab) / Mitsubishi Tanabe, J&J
Micro‐fragmented autologous adipose tissue injection for fistula‐in‐ano (MAATIFA) in patients with Crohn’s disease: a prospective observational study (ESCP 2019) – Sep 28, 2019 – Abstract #P453; “Results Ten patients underwent the procedure in the time interval between two biologic drug administration (6 infliximab –4 adalimumab). Conclusion Micro-fragmented autologous adipose tissue injection showed promising results in promoting Crohn’s-related complex anal fistula healing. These good results are probably related to the reduction of inflammation and the activation of a reparative mechanisms.”

 

Xeljanz (tofacitinib) / Pfizer
Xeljanz sales projection: $2.2B in 2019, $3B in 2020 and $4.1B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 725; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Simponi WW sales projection: $3B in 2019 and $3.7B in 2024 (Cowen & Co) – Sep 26, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2876; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Humira (adalimumab) / Eisai, AbbVie
Humira patent protection: Until 2022-2034 (Cowen & Co) – Sep 28, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2872; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Health Care Research, et al; DATE: 09/17/2019

 

mirikizumab (LY3074828) / Eli Lilly
Phase 3 initiation of mirikizumab, a candidate drug for the treatment of immune diseases, for patients with moderate and severe active Crohn’s disease [Google Translation] (Newsmp) – Sep 24, 2019 – “Lilly Korea will conduct a phase 3 clinical trial of a candidate drug for treating immunological diseases in patients with Crohn’s disease in Korea. The Ministry of Food and Drug Safety approved the phase 3 trial of Mirikizumab…filed by Lilly Korea.”

 

Stelara (ustekinumab) / J&J
Stelara WW sales projection: $6.2B in 2019, $7B in 2020 and $10B in 2024 (Cowen & Co) – Sep 26, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2917; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Humira (adalimumab) / Eisai, AbbVie
Humira patent expiry: January 2023 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 715; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Entyvio (vedolizumab) / Takeda
Limit therapies [Google Translation] (Nasz Dziennik) – Sep 23, 2019 – “Crohn patients are also waiting for the drug vedolizumab (Entyvio) used in many EU countries. In the message sent to us, the Ministry of Health ensures that the specific product will soon be available in Poland. ‘Entyvio (vedolizumab) will be reimbursed from November 1, 2019 as part of a drug program for the treatment of severe, active Crohn’s disease as another therapeutic option in addition to infliximab and adalimumab,’ reads the letter.”

Read More …

Weekly Top News – Psoriasis – September 30, 2019

September 30, 2019

Taltz (ixekizumab) / Eli Lilly
Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis (EADV 2019) – Sep 24, 2019 – Abstract #D3T01.1B; Pres time: Oct 12, 2019; 08:45 AM – 09:00 AM; Location: Hall 10 Dalí; No abstract available.

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi sales projection: $250M in 2019, $850M in 2020 and $3B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 491; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Taltz (ixekizumab) / Eli Lilly
Taltz sales projection: $1.38B in 2019, $1.93B in 2020 and $3.1B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 484; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019
Sales projection

Otezla (apremilast) / Amgen
Otezla sales projection: $3B in 2024 (Cowen & Co) – Sep 26, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2914; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Stelara (ustekinumab) / J&J
Stelara WW sales projection: $9B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 479; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Cosentyx (secukinumab) / Novartis
Cosentyx sales projection: $3.27B in 2019, $3.59B in 2020 and $5.1B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 487; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019
Sales projection

Stelara (ustekinumab) / J&J
Stelara WW sales projection: $6.2B in 2019, $7B in 2020 and $10B in 2024 (Cowen & Co) – Sep 26, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2917; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Tremfya (guselkumab) / J&J
Tremfya WW sales projection: >$2.5B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 481; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Now comes a new effective medicine for psoriasis [Google Translation] – Sep 24, 2019 – “Decision forums have given thumbs to Skyrizi – AbbVie’s innovative drug for plaque psoriasis. – Skyrizi is cost-effective and has a well-documented effect. We are therefore pleased to be able to offer patients this drug, says the head of the Decision Forum Stig A. Slørdahl….We look forward to seeing more of the two-year data from the IMMhance study at the World Congress of Dermatology in June 2020…”

Read More …

ASCO 2019 Demographics, Chicago, IL

September 25, 2019

by Sam SzentmiklosyDigital Media Specialist


 

The American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 31 – June 4, 2019 in Chicago, IL.  ASCO recently released their demographics for 2019 and we are going to compare the numbers from 2018.

 

In 2019, there was a total of 42,500 attendees, a 4.4% increase from 2018 which had a total of 40,700 attendees.  Out of the 42,500 attendees, 34,250 were professionals and 6,216 were exhibitors.  The top countries in attendance in 2019 are the United States and China whereas in 2018, it was the US and Canada.  This year, 55% of attendees were international while in 2018, 2% of guests were international.  It’s clear that the numbers in 2019 have greatly increased since 2018 which is wonderful to see.

 

People attend the ASCO Annual Meeting every year and these increasing numbers show that more people have come together to meet each other, take in new information, and grow more within their skills and fields.  Guests’ roles ranged from oncologists, pharmacists, biologists, researchers, and more.

 

 

Connecting with our clients is always a pleasure and these conferences give us the opportunity to say hello and touch base. We are always looking to attend conferences. Follow us on Twitter to stay up to date on our upcoming events or visit our website.

Read More …

Weekly Top News – Breast Cancer – September 23, 2019

September 23, 2019

Tecentriq (atezolizumab) / Roche
Tecentriq: Data from P3 IMpassion031 trial (NCT03197935) for neoadjuvant TNBC in 2020 (Roche) – Sep 17, 2019 – Pharma Day: Data from P3 IMvigor010 trial (NCT02450331) as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer in 2020 
[Screenshot]

 

Keytruda (pembrolizumab) / Merck (MSD)
Keytruda clinical trial estimate: Data from P3 KEYNOTE-355 trial (NCT02819518) for 1L TNBC in early 2020 (Morgan Stanley) – Sep 20, 2019 – A subscription to Thomson ONE is required to gain full access to report 67912369; Page no: 7; REPORT TITLE: “Pharmaceuticals: Specialist prescribing dynamics: Focus on oncology”; AUTHOR: Purcell, Mark, et al; DATE: 09/05/2019

 

Verzenio (abemaciclib) / Eli Lilly
Lilly’s MONARCH plus study reaches primary endpoint (GBI Health) – Sep 20, 2019 – P3, N=463; MONARCH plus (NCT02763566); Sponsor: Eli Lilly and Company; “US major Eli Lilly’s MONARCH plus Phase III clinical study for protease inhibitor abemaciclib has met the company’s expectations. After receiving an abemaciclib treatment in combination with an aromatase inhibitor (anastrozole/letrozole) or fulvestrant, HR+/HER2- pre-menopausal advanced breast cancer Chinese female patients with tumor progression who had been previously treated with endocrine therapy saw their progression free survival (PFS) significantly prolonged, and experienced good tolerance towards the drug. Furthermore, the safety spectrum is consistent with previous clinical studies.”

 

Tecentriq (atezolizumab) / Roche
Chugai obtains approval for additional indication and formulation for Tecentriq in PD-L1-positive triple negative breast cancer (Chugai Press Release) – Sep 20, 2019 – “Chugai Pharmaceutical Co., Ltd…announced…that it has obtained regulatory approval for its humanized anti-PD-L1 monoclonal antibody, Tecentriq® [generic name: atezolizumab (genetical recombination)] from the Ministry of Health, Labour and Welfare (MHLW) for an additional indication of PD-L1-positive, hormone receptor-negative and HER2-negative inoperable or metastatic breast cancer. It has also obtained approval for an additional formulation of Tecentriq 840 mg. Tecentriq 840 mg was developed to provide an optimal formulation for breast cancer for which approved dosage is 840 mg once every 2 weeks.”

 

Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer; Ibrance (palbociclib) / Pfizer; Bavencio (avelumab) / EMD Serono, Pfizer; Xtandi (enzalutamide) / Pfizer, Astellas
Pfizer presents scientific advancements in cancer care at the ESMO Congress 2019 highlighting expanded portfolio (Businesswire) – Sep 19, 2019 – P3, N=645; BEACON CRC (NCT02928224); Sponsor: Array BioPharma; P3, N=886; JAVELIN Renal 101 (NCT02684006); Sponsor: Pfizer; P1, N=147; NCT02573259; Sponsor: Pfizer; “Pfizer Inc….is presenting data across its industry-leading oncology portfolio, including company-sponsored and collaborative research studies, spanning 11 therapies in 22 types of cancer, at the European Society for Medical Oncology (ESMO) Congress to be held in Barcelona, Spain, September 27 – October 1, 2019. Data from nearly 50 abstracts involving Pfizer cancer medicines will illustrate the diversity of the portfolio and the company’s cutting-edge scientific approach. For the first time, this will include data presentations on compounds from the acquisition of Array Biopharma Inc.”

 

Ibrance (palbociclib) / Pfizer; Kisqali (ribociclib) / Novartis; Verzenio (abemaciclib) / Eli Lilly
FDA warns against pneumonitis with CDK 4/6 inhibitor drugs for breast cancer (Korea Biomedical Review) – Sep 16, 2019 – “The U.S. Food and Drug Administration added a warning that the entire class of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor drugs for breast cancer could cause pneumonitis. However, the regulator made it clear that the medicines’ overall benefit was still greater than the risks for advanced breast cancer patients. The FDA said on Friday that Pfizer’s Ibrance (ingredient: palbociclib), Novartis’ Kisqali (ribociclib), and Lilly’s Verzenio (abemaciclib) might cause rare but severe lung inflammation in patients with advanced breast cancer.”

 

Kisqali (ribociclib) / Novartis
Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer (Canada Newswire) – Sep 19, 2019 – “Novartis Pharmaceuticals Canada Inc… is pleased to announce that Quebec will now reimburse KISQALI® (ribociclib) for eligible patients in combination with an aromatase inhibitor (letrozole) under the province’s public drug program for first-line treatment of postmenopausal women living with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.”access to treatment for metastatic breast cancer.”

 

Keytruda (pembrolizumab) / Merck (MSD); Bria-IMT (SV-BR-1-GM) / BriaCell
BriaCell announces public disclosure: Remarkable responder in combination study of lead candidate with Keytruda (GlobeNewswire) – Sep 19, 2019 – P1/2a, N=40; NCT03328026; Sponsor: BriaCell Therapeutics Corporation; “The top responder…in the Combination Study experienced a highly remarkable reduction in breast cancer tumors….She showed one of the best immune responses and displayed a highly remarkable reduction in breast cancer tumors (metastases) in the adrenal gland and the outer lining of the brain…The data presented today also noted that the Bria-IMT™ regimen administered with KEYTRUDA® was safe and well tolerated. The women who showed the best clinical responses to the combination of the Bria-IMT™ regimen with KEYTRUDA® also showed the best immune responses including a cellular immune response…”

 

Keytruda (pembrolizumab) / Merck (MSD); Bria-IMT (SV-BR-1-GM) / BriaCell
BriaCell to present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia (GlobeNewswire) – Sep 16, 2019 – P1/2, N=40; NCT03328026; Sponsor: BriaCell Therapeutics Corporation; “BriaCell Therapeutics Corp….announces that the Company will be presenting at the 2nd Annual Next Gen Immuno-Oncology Congress, taking place September 19-20, 2019 at Hilton Garden Inn, Philadelphia Center City….present the latest clinical findings of the Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination Study with pembrolizumab…”

Read More …

Weekly Top News – IBD – September 23, 2019

September 23, 2019

filgotinib (GLPG0634) / Gilead
Filgotinib clinical trial estimate: Data from P3 Diversity1 trial (NCT02914561) for Crohn’s disease in Q2 2021 (Morgan Stanley) – Sep 18, 2019 – A subscription to Thomson ONE is required to gain full access to report 67932681; Page no: 4; REPORT TITLE: “Galapagos NV: Large differentiated pipeline headlined by Filgotinib, resume at OW”; AUTHOR: Harrison, Matthew, et al; DATE: 09/08/2019

 

etrolizumab (RG7413) / Roche
Etrolizumab: Data from P3 HIBISCUS 1 trial (NCT02163759) for ulcerative colitis in 2020 (Roche) – Sep 17, 2019 – Pharma Day 2019: Data from P3 HIBISCUS 2 trial (NCT02171429) for TNF naive ulcerative colitis in 2020 
[Screenshot]

 

etrolizumab (RG7413) / Roche
Etrolizumab: Data from P3 HICKORY trial (NCT02100696) for ulcerative colitis in 2020 (Roche) – Sep 17, 2019 – Pharma Day 2019: Data from P3 BERGAMOT trial (NCT02394028) for moderate-to-severe Crohn’s disease in 2021 
[Screenshot]

 

etrolizumab (RG7413) / Roche
Etrolizumab: Data from P3 LAUREL trial (NCT02165215) for ulcerative colitis in 2020 (Roche) – Sep 17, 2019 – Pharma Day 2019: Data from P3 GARDENIA trial (NCT02136069) for moderate to severe ulcerative colitis in 2020
P3 data
[Screenshot]

foralumab (TZLS-401) / Tiziana Life Sciences
Tiziana Life Sciences announces FDA approval to initiate phase I clinical trial with orally administered foralumab in healthy volunteers (Businesswire) – Sep 16, 2019 – “Tiziana Life Sciences plc…is pleased to announce…that the U.S. Food and Drug Administration (FDA) has allowed the initiation of a Phase I clinical trial in healthy volunteers using a novel oral enteric-coated capsule formulation of Foralumab….This is the first clinical trial in which Foralumab will be administered orally to healthy subjects.”

 

Tremfya (guselkumab) / J&J
Tremfya sales projection: $3B in 2024 (MainFirst Bank AG) – Sep 16, 2019 – A subscription to Thomson ONE is required to gain full access to report 67932139; Page no: 30; REPORT TITLE: “MainFirst AG- Initiating coverage: MainFirst: Morphosys AG (OPF / EUR 140): On the cusp of transformation supported by a fat wallet”; AUTHOR: Wieprecht, Marcus, et al; DATE: 09/08/2019

 

Stelara (ustekinumab) / J&J
Stelara WW sales projection: $9B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 479; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Humira (adalimumab) / Eisai, AbbVie
Humira patent expiry: January 2023 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 715; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Rinvoq (upadacitinib) / AbbVie
Rinvoq: Newly added patents in Orange Book (Orange Book) – Sep 18, 2019 – Expiry of patents on December 1, 2030, January 15, 2031, October 17, 2036 
[Screenshot]

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi sales projection: $250M in 2019, $850M in 2020 and $3B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 491; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

Read More …

Weekly Top News – Psoriasis – September 23, 2019

September 23, 2019

Tremfya (guselkumab) / J&J
Janssen submits application to U.S. FDA seeking first-in-class approval of Tremfya (guselkumab) for treatment of adults with active psoriatic arthritis (PRNewswire) – Sep 16, 2019 – “The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of TREMFYA (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)….Janssen also expects to submit a marketing application to the European Medicines Agency seeking approval of TREMFYA as a treatment for PsA before the end of the year.”

 

Taltz (ixekizumab) / Eli Lilly
Taltz pricing: Wholesale acquisition cost of $5,162/Injection (J.P. Morgan) – Sep 20, 2019 – A subscription to Thomson ONE is required to gain full access to report 67963077; Page no: 20; REPORT TITLE: “European Pharmaceuticals: Weekly Chartbook: trx for week ending September 6th”; AUTHOR: Vosser, Richard, et al; DATE: 09/15/2019

 

Tremfya (guselkumab) / J&J
Tremfya pricing: Wholesale acquisition cost of $10,859/Injection (J.P. Morgan) – Sep 20, 2019 – A subscription to Thomson ONE is required to gain full access to report 67963077; Page no: 20; REPORT TITLE: “European Pharmaceuticals: Weekly Chartbook: trx for week ending September 6th”; AUTHOR: Vosser, Richard, et al; DATE: 09/15/2019

 

Cosentyx (secukinumab) / Novartis
Cosentyx pricing: Wholesale acquisition cost of $5,179/Injection (J.P. Morgan) – Sep 20, 2019 – A subscription to Thomson ONE is required to gain full access to report 67963077; Page no: 20; REPORT TITLE: “European Pharmaceuticals: Weekly Chartbook: trx for week ending September 6th”; AUTHOR: Vosser, Richard, et al; DATE: 09/15/2019

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi sales projection: $250M in 2019, $850M in 2020 and $3B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 491; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Tremfya (guselkumab) / J&J
Tremfya WW sales projection: >$2.5B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 481; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Taltz (ixekizumab) / Eli Lilly
Taltz sales projection: $1.38B in 2019, $1.93B in 2020 and $3.1B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 484; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Cosentyx (secukinumab) / Novartis
Cosentyx sales projection: $3.27B in 2019, $3.59B in 2020 and $5.1B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 487; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Stelara (ustekinumab) / J&J
Stelara WW sales projection: $9B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 479; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

Read More …

Weekly Top News – Breast Cancer – September 16, 2019

September 16, 2019

Verzenio (abemaciclib) / Eli Lilly
Verzenio: Data from P3 MONARCH-2 trial (NCT02107703) in HER2- breast cancer at ESMO (September 27 – October 1, 2019) (Eli Lilly) – Sep 10, 2019 – World Lung: Data from P2 monarcHER trial (NCT02675231) in metastatic breast cancer at ESMO (September 27 – October 1, 2019) 
[Screenshot]

 

[fam-] trastuzumab deruxtecan (DS-8201) / Daiichi Sankyo, AstraZeneca
Daiichi Sankyo advances [fam-] trastuzumab deruxtecan (DS-8201) in Japan with regulatory submission in HER2 positive metastatic breast cancer (Daiichi Sankyo Press Release) – Sep 9, 2019 – “Daiichi Sankyo Company…today announced the submission of a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for the use of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), for the treatment of patients with HER2 positive metastatic breast cancer…’We are proud to initiate this critical next step in the regulatory process in Japan and look forward to the presentation of the phase 2 DESTINY-Breast01 study of [fam-] trastuzumab deruxtecan to the scientific community,’ said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo.”

 

Ibrance (palbociclib) / Pfizer; Kisqali (ribociclib) / Novartis; Verzenio (abemaciclib) / Eli Lilly
FDA warns against pneumonitis with CDK 4/6 inhibitor drugs for breast cancer (Korea Biomedical Review) – Sep 16, 2019 – “The U.S. Food and Drug Administration added a warning that the entire class of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor drugs for breast cancer could cause pneumonitis. However, the regulator made it clear that the medicines’ overall benefit was still greater than the risks for advanced breast cancer patients. The FDA said on Friday that Pfizer’s Ibrance (ingredient: palbociclib), Novartis’ Kisqali (ribociclib), and Lilly’s Verzenio (abemaciclib) might cause rare but severe lung inflammation in patients with advanced breast cancer.”

 

Nerlynx (neratinib) / Puma
Puma Biotechnology announces U.S. FDA acceptance of Supplemental New Drug Application for neratinib to treat HER2-positive metastatic breast cancer (Businesswire) – Sep 11, 2019 – “Puma Biotechnology, Inc….announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed therapy (third-line disease)….The FDA confirmed that the review will have an action date of late April, 2020….The sNDA is supported by the results of the Phase III NALA trial…”

 

Herzuma (trastuzumab biosimilar) / Nippon Kayaku, Pfizer, Mundipharma, Celltrion, Teva
Canada OKs Celltrion’s biosimilar (Korea Biomedical Review) – Sep 10, 2019 – “Celltrion said that Health Canada has given the go-ahead for Herzuma (Ingredient: Trastuzumab), an anticancer antibody biosimilar, in treating breast and gastric cancer.”

 

Piqray (alpelisib) / Novartis
Novartis’s kinase inhibitor Piqray makes its way into Latin America (GBI Health) – Sep 11, 2019 – “The National Health Surveillance Agency (ANVISA) this week granted Brazil market clearance to Switzerland-based Novartis’s oncology treatment Piqray (alpelisib), as GBI analysis reveals. The oral drug is developed to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. However, the agency is yet to publish indication details.”

 

Lynparza (olaparib) / Merck (MSD), AstraZeneca; Keytruda (pembrolizumab) / Merck (MSD)
Pivotal new data from Merck’s broad oncology portfolio at ESMO 2019 Congress (Merck (MSD) Press Release) – Sep 9, 2019 – “Merck…announced new data from its broadoncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, from Sept. 27-Oct. 1, 2019. More than 80 abstracts involving Merck cancer medicines and investigational candidates will be featured at the congress, spanning over 18 tumor types. Three of these abstracts – KEYTRUDA data in triple-negative breast cancer (TNBC), LYNPARZA data in prostate cancer and LYNPARZA data in ovarian cancer – were selected for inclusion in the ESMO Presidential Symposium sessions.”

 

Keytruda (pembrolizumab) / Merck (MSD); Bria-IMT (SV-BR-1-GM) / BriaCell
BriaCell to present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia (GlobeNewswire) – Sep 16, 2019 – P1/2, N=40; NCT03328026; Sponsor: BriaCell Therapeutics Corporation; “BriaCell Therapeutics Corp….announces that the Company will be presenting at the 2nd Annual Next Gen Immuno-Oncology Congress, taking place September 19-20, 2019 at Hilton Garden Inn, Philadelphia Center City….present the latest clinical findings of the Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination Study with pembrolizumab…”

 

leronlimab (PRO 140) / CytoDyn
CytoDyn Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer (GlobeNewswire, CytoDyn Inc.) – Sep 9, 2019 – “CytoDyn Inc…announced today that the FDA has allowed a Phase 2 study to proceed for combination therapy of leronlimab and Regorafenib in patients with metastatic colorectal cancer (mCRC). The study will be conducted by lead principal investigator, John L. Marshall, M.D., Director, The Ruesch Center for the Cure of GI Cancers Frederick P. Smith Endowed Chair, Chief, Hematology and Oncology Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. “We have completed our safety review of your application and have concluded that you may proceed with your proposed clinical investigation of Protocol number CD08_mCRC, entitled, “A Phase II Study of Leronlimab (PRO 140) in combination with Regorafenib…”

 

Tecentriq (atezolizumab) / Roche
Tecentriq sales projection: Consensus of $4.2B in 2023 and $4.8B peak (Morgan Stanley) – Sep 13, 2019 – A subscription to Thomson ONE is required to gain full access to report 67912369; Page no: 7; REPORT TITLE: “Pharmaceuticals: Specialist prescribing dynamics: Focus on oncology”; AUTHOR: Purcell, Mark, et al; DATE: 09/05/2019

 

Imfinzi (durvalumab) / AstraZeneca, Celgene
Imfinzi sales projection: $3.8B peak (J.P. Morgan) – Sep 14, 2019 – A subscription to Thomson ONE is required to gain full access to report 67911951; Page no: 29; REPORT TITLE: “European Pharma & Biotech: back to school: We still prefer the large ones: Overweight Novo, Astra & Roche”; AUTHOR: Vosser, Richard, et al; DATE: 09/04/2019

Read More …

Weekly Top News – IBD – September 16, 2019

September 16, 2019

oral etanercept (OPRX-106) / Protalix
OPRX-106 clinical trial estimate: Data from P2 trial (NCT02768974) for ulcerative colitis in H2 2019 (Jefferies) – Sep 10, 2019 – A subscription to Thomson ONE is required to gain full access to report 67787343; Page no: 1; REPORT TITLE: “Protalix Biotherapeutics Inc Go-ahead for expedited US path; PRX-102 filing expected in 1Q20”; AUTHOR: Welford, Peter, et al; DATE: 08/08/2019

 

PTG-200 / Protagonist Therapeutics, J&J
PTG-200: Data from P1 trial in healthy volunteers in 2019 (H.C. Wainwright Global Life Sciences Conference 2019, Protagonist Therapeutics) – Sep 11, 2019 
[Screenshot]

 

Remicade (infliximab) / Mitsubishi Tanabe, J&J
Remicade pricing: $28,906/year (Infinata) – Sep 11, 2019 – A subscription to Thomson ONE is required to gain full access to report 67557275; Page no: 8; REPORT TITLE: “UCB S.A. – Company report”; AUTHOR: Infinata, et al; DATE: 09/03/2019

 

Otezla (apremilast) / Amgen
Otezla sales projection: $2.1B in 2020 (CFRA) – Sep 10, 2019 – A subscription to Thomson ONE is required to gain full access to report 67896905; Page no: 5; REPORT TITLE: “Amgen Inc.”; AUTHOR: Huang, Kevin, et al; DATE: 08/31/2019

 

Rinvoq (upadacitinib) / AbbVie
Rinvoq sales projection: $236M for ulcerative colitis in 2026 and $690M for ulcerative colitis and Crohn’s disease in 2030 (Infinata) – Sep 10, 2019 – A subscription to Thomson ONE is required to gain full access to report 67557855; Page no: 12; REPORT TITLE: “AbbVie Inc. – Company report”; AUTHOR: Infinata, et al; DATE: 09/03/2019

 

Entyvio (vedolizumab) / Takeda
Entyvio sales projection: $4,425M by 2025 (GlobalData) – Sep 11, 2019 – A subscription to Thomson ONE is required to gain full access to report 67577535; Page no: 64; REPORT TITLE: “Takeda Pharmaceutical Co Ltd (4502) – Financial and strategic SWOT analysis review”; AUTHOR: Globaldata, et al; DATE: 09/05/2019

 

Stelara (ustekinumab) / J&J
Serum Institute unveils ₹4,000-cr plant in Pune (The Hindu Business Line) – Sep 9, 2019 – “Union Health Minister…on Monday inaugurated Serum Institute of India’s (SII) new plant with an investment of ₹4,000 crore at Manjri in Pune. The new unit, which will commence operations from November…The unit is built in compliance with the US and European vaccine manufacturing regulations….It will maximise the production of…monoclonal antibodies like…Ustekinumab (Stelara®).”

 

Tremfya (guselkumab) / J&J
Tremfya sales projection: $3B in 2024 (MainFirst Bank AG) – Sep 16, 2019 – A subscription to Thomson ONE is required to gain full access to report 67932139; Page no: 30; REPORT TITLE: “MainFirst AG- Initiating coverage: MainFirst: Morphosys AG (OPF / EUR 140): On the cusp of transformation supported by a fat wallet”; AUTHOR: Wieprecht, Marcus, et al; DATE: 09/08/2019

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi WW sales projection: $300M in FY2019 and $800M in FY2020 (Piper Jaffray) – Sep 9, 2019 – A subscription to Thomson ONE is required to gain full access to report 67909429; Page no: 1; REPORT TITLE: “Abbvie Inc – Skyrizi En Fuego – New derm survey indicates Q219 was no fluke”; AUTHOR: Raymond, Christopher, et al; DATE: 09/04/2019

Read More …

Weekly Top News – Psoriasis – September 16, 2019

September 16, 2019

ANB019 / AnaptysBio
ANB019 regulatory estimate: Approval for palmo-plantar pustular psoriasis in US/EU in 2022 (Jefferies) – Sep 11, 2019 – A subscription to Thomson ONE is required to gain full access to report 67790601; Page no: 2; REPORT TITLE: “AnaptysBio Inc – Q2′ 19: Key readouts approaching to the end of the year”; AUTHOR: Amin, Biren, et al; DATE: 08/08/2019

 

ANB019 / AnaptysBio
ANB019 regulatory estimate: Approval for generalized pustular psoriasis in US in 2021 and EU in 2022 (Jefferies) – Sep 11, 2019 – A subscription to Thomson ONE is required to gain full access to report 67790601; Page no: 2; REPORT TITLE: “AnaptysBio Inc – Q2′ 19: Key readouts approaching to the end of the year”; AUTHOR: Amin, Biren, et al; DATE: 08/08/2019

Tremfya (guselkumab) / J&J
Janssen submits application to U.S. FDA seeking first-in-class approval of Tremfya (guselkumab) for treatment of adults with active psoriatic arthritis (PRNewswire) – Sep 16, 2019 – “The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of TREMFYA (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)….Janssen also expects to submit a marketing application to the European Medicines Agency seeking approval of TREMFYA as a treatment for PsA before the end of the year.”

 

ANB019 / AnaptysBio
ANB019 clinical trial estimate: Data from P2 GALLOP trial (NCT03619902) for generalized pustular psoriasis in Q4 2019 (Wedbush) – Sep 11, 2019 – A subscription to Thomson ONE is required to gain full access to report 67796743; Page no: 2; REPORT TITLE: “AnaptysBio Inc – 2Q19 financials; Topline ANB019 data imminent, Ph 2b atopic derm data in Q4”; AUTHOR: Nierengarten, David, et al; DATE: 08/09/2019

 

Otezla (apremilast) / Amgen
Otezla sales projection: $2.1B in 2020 (CFRA) – Sep 10, 2019 – A subscription to Thomson ONE is required to gain full access to report 67896905; Page no: 5; REPORT TITLE: “Amgen Inc.”; AUTHOR: Huang, Kevin, et al; DATE: 08/31/2019

 

Stelara (ustekinumab) / J&J
Serum Institute unveils ₹4,000-cr plant in Pune (The Hindu Business Line) – Sep 9, 2019 – “Union Health Minister…on Monday inaugurated Serum Institute of India’s (SII) new plant with an investment of ₹4,000 crore at Manjri in Pune. The new unit, which will commence operations from November…The unit is built in compliance with the US and European vaccine manufacturing regulations….It will maximise the production of…monoclonal antibodies like…Ustekinumab (Stelara®).”

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi WW sales projection: $300M in FY2019 and $800M in FY2020 (Piper Jaffray) – Sep 9, 2019 – A subscription to Thomson ONE is required to gain full access to report 67909429; Page no: 1; REPORT TITLE: “Abbvie Inc – Skyrizi En Fuego – New derm survey indicates Q219 was no fluke”; AUTHOR: Raymond, Christopher, et al; DATE: 09/04/2019

 

Cosentyx (secukinumab) / Novartis; Taltz (ixekizumab) / Eli Lilly; Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko Kirin
AllianceRx Walgreens Prime study demonstrates increased adherence and improvement in symptoms for psoriasis patients switching to interleukin-17 inhibitors (PRNewswire) – Sep 11, 2019 – “AllianceRx Walgreens Prime announced results from a new study analyzing data from patients prescribed interleukin-17 (IL-17) inhibitors for psoriasis. Patients reported improvements in psoriatic symptoms and demonstrated increased medication adherence after switching to one of the three IL-17 medications included in the study….Studies have shown that inhibiting IL-17 can help clear psoriasis. Newer biologic medications, such as secukinumab, ixekizumab or brodalumab, focus on inhibiting IL-17.”

Read More …
« Older Entries